Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
A biologic drug derived from enzymatic hydrolysis of porcine brain tissue, containing low-molecular-weight peptides and free amino acids. Manufactured by EVER Pharma and registered in 50+ countries (not FDA-approved in the US) for ischemic stroke, TBI, and dementia.
0 of 1 vendors lab-verified
Verified purity per dollar — the cheapest that's actually been tested
vial · 60mg· optimasupply.is· price updated today
$69.99✓ $1.17/mg
single-vial price — packs may be lower
vial · 60mg· peptidetech.is· price updated 1w ago
$74.99$1.25/mg
single-vial price — packs may be lower
4 vendors not shown — trust grade below C, or not enough verified COA data yet. We only list sources with a C grade or better.
Single-vial list prices by default for a fair head-to-head — switch to Multi-vial / bulk for pack pricing. Estimates only; verify at vendor before purchase. For research use only. Not medical advice.
Best price trend
Lowest $/mg for Cerebrolysin · verified listings only
$1.17/mg
▼ 6% over 90d
Optima Supply has the lowest single-vial Cerebrolysin price at $1.17/mg among 2 COA-verified vendors on Disclosed Labs. Bulk or multi-vial deals may be lower. That's 7% less per mg than the most expensive option.
What is the price range for Cerebrolysin?
Research-grade Cerebrolysin ranges from $1.17/mg to $1.25/mg across 2 verified sources, a 7% spread per mg.
How are Cerebrolysin prices verified on Disclosed Labs?
Every listed vendor holds a Grade C or better trust score, computed independently from lab Certificates of Analysis — not from payments or sponsorships. Prices are scraped and fact-checked daily. Vendors cannot pay to improve their ranking.
Check formulation: Lyophilized powder requires reconstitution before use. Pre-mixed solutions are more convenient but may have a shorter shelf life and higher prices.
Compare per-mg cost: Different strengths and quantities make direct price comparison difficult. Calculate the per-milligram cost to find the true best value.
Verify COAs: Look for vendors that publish per-batch Certificates of Analysis from named, accredited labs. Use the Full safety panel filter to require endotoxin, sterility, and heavy-metals testing on the current batch — not just HPLC purity.
The CASTA trial (Heiss et al., Stroke 2012, PMID 22282884, n=1070) failed its primary endpoint in Asian ischemic stroke patients, though a post-hoc subgroup with NIHSS >12 showed favorable mortality and functional trends. The CARS trial (Muresanu et al., Stroke 2016, PMID 26564102) reported improved upper-extremity motor recovery at day 90 with 30 mL/d for 21 days alongside rehabilitation. The Guekht 2011 vascular-dementia RCT (PMID 20656516, n=242) reported ADAS-cog+ and CIBIC+ improvements vs placebo. A 2023 Cochrane review (Ziganshina et al., PMID 37818733) concluded moderate-certainty evidence that Cerebrolysin/Cerebrolysin-like peptide mixtures probably do not reduce all-cause death in acute ischemic stroke, and flagged a possible increase in non-fatal serious adverse events. Many pivotal trials are industry-sponsored, and batch-to-batch variability as a porcine-brain hydrolysate is an ongoing methodological concern.
This platform provides informational tools only, not medical advice.
Heiss WD et al. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial (CASTA). Stroke 2012;43(3):630-636
2012
Muresanu DF et al. Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. Stroke 2016;47(1):151-159
2016
Guekht AB et al. Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial. J Stroke Cerebrovasc Dis 2011;20(4):310-318
Prices verified as of July 2026. Actual prices may vary. For research use only.
2011
Disclosed Labs